Beijing Saifu Pharmaceutical Research Institute

About Beijing Saifu Pharmaceutical Research Institute

Beijing Saifu Pharmaceutical Research Institute Co., Ltd., operating as SAFE Pharma, is a contract research organization (CRO) established in 2016. The company was founded by a team of researchers with scientific backgrounds from the Chinese Academy of Sciences, with Mr. Liu Yang serving as Chairman and CEO. Headquartered in Beijing, SAFE Pharma has expanded its presence with branches in Suzhou, Shenzhen, Chengdu, Shenyang, and the United States, positioning itself as a key player in China's pharmaceutical research and development sector.

SAFE Pharma functions as a one-stop, preclinical CRO, providing comprehensive services to support the development of innovative drugs for both domestic and international clients. The firm's business model is centered on offering contract research services to biotech and pharmaceutical companies, thereby generating revenue through service fees. Its client base consists of entities engaged in developing novel therapies. The organization specializes in the toxicological testing and safety evaluation of drugs, a critical component of the preclinical phase. This focus addresses the growing demand for high-quality, technically sophisticated preclinical services, particularly in Good Laboratory Practice (GLP) safety evaluations.

The company provides an extensive portfolio of services, including NMPA/FDA registration and declaration, antibody drug discovery, AI-driven and organoid-based early drug screening, and evaluations of pharmacodynamics and pharmacokinetics. Its core expertise is particularly noted in the fields of cell and gene therapy (CGT), vaccines, nucleic acid drugs, and antibody-drug conjugates (ADCs). Over the years, SAFE Pharma has supported thousands of research projects, helping numerous innovative drugs successfully navigate the Investigational New Drug (IND) and New Drug Application (NDA) processes. The company has received multiple rounds of significant funding, including a RMB 300 million Series C in 2021 and a RMB 500 million Series D in 2022, which have been instrumental in enhancing its service capabilities and production capacity.